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Abstract
Peripheral muscarinic acetylcholine receptors regulate insulin and glucagon release in
rodents but their importance for similar roles in humans is unclear. Bethanechol, an acetyl-
choline analogue that does not cross the blood-brain barrier, was used to examine the role
of peripheral muscarinic signaling on glucose homeostasis in humans with normal glucose
tolerance (NGT; n = 10), impaired glucose tolerance (IGT; n = 11), and type 2 diabetes melli-
tus (T2DM; n = 9). Subjects received four liquid meal tolerance tests, each with a different
dose of oral bethanechol (0, 50, 100, or 150 mg) given 60 min before a meal containing
acetaminophen. Plasma pancreatic polypeptide (PP), glucose-dependent insulinotropic
polypeptide (GIP), glucagon-like peptide-1 (GLP-1), glucose, glucagon, C-peptide, and
acetaminophen concentrations were measured. Insulin secretion rates (ISRs) were calcu-
lated from C-peptide levels. Acetaminophen and PP concentrations were surrogate mark-
ers for gastric emptying and cholinergic input to islets. The 150 mg dose of bethanechol
increased the PP response 2-fold only in the IGT group, amplified GLP-1 release in the IGT
and T2DM groups, and augmented the GIP response only in the NGT group. However,
bethanechol did not alter ISRs or plasma glucose, glucagon, or acetaminophen concentra-
tions in any group. Prior studies showed infusion of xenin-25, an intestinal peptide, delays
gastric emptying and reduces GLP-1 release but not ISRs when normalized to plasma glu-
cose levels. Analysis of archived plasma samples from this study showed xenin-25 ampli-
fied postprandial PP responses ~4-fold in subjects with NGT, IGT, and T2DM. Thus,
increasing postprandial cholinergic input to islets augments insulin secretion in mice but not
humans.
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Introduction
Transmitters and peptides released from neurons that innervate islets play important roles in
regulating insulin and glucagon release [1,2]. In general, parasympathetic and sympathetic
neurons that innervate pancreatic islets increase and inhibit insulin release, respectively [1–4].
In rodents, islets are richly innervated by parasympathetic neurons [5]. Previous studies from
our laboratory have shown that a cholinergic neural relay amplifies the effects of glucose-
dependent insulinotropic polypeptide (GIP) on insulin release in mice [6]. Studies by others
using genetically modified mice and/or islets indicate that cholinergic signaling via M3 musca-
rinic acetylcholine receptors plays an important role in regulating insulin and glucagon release
[7–12]. Consistent with mouse experiments, studies with the isolated perfused human pancreas
have shown that electrical stimulation of the splanchnic nerve in the presence and absence of
selective neural inhibitors increases both cholinergic and sympathetic input to islets which in
turn, regulates insulin, glucagon, pancreatic polypeptide (PP), and somatostatin release [13–
18]. Further, neurotransmitters regulate insulin release in isolated human islets [19]. In con-
trast to the in situ and ex vivo studies, physiologic stimuli (e.g. nutrients, stress) would differen-
tially affect parasympathetic versus sympathetic input to islets. Thus, the physiologic relevance
of the electrical stimulation and human islet studies is not clear.
There are conflicting reports on the effects of physiologic levels of cholinergic signaling for
regulating insulin and glucagon responses in vivo in humans. For example, prior prolonged
mild hyperglycemia results in a compensatory increase in C-peptide secretion during intrave-
nous glucose tolerance tests, which is only partially inhibited by atropine [20]. In another
study, atropine inhibited the cephalic insulin response to meal ingestion by 20% [21] Specific
anti-psychotic medications that are associated with development of T2DM also exhibit second-
ary affinity/antagonism to muscarinic M3 receptors [22]. During 50-gram oral glucose toler-
ance tests, areas under the curve for glucose, glucagon-like peptide-1 (GLP-1), and insulin
secretion rates (ISRs) were increased in humans with truncal vagotomy plus pyloroplasty com-
pared to controls [23]. However, these changes are likely indirect because vagotomy also
increased the rate of gastric emptying. Conversely, vagotomy for peptide ulcer disease had little
effect on plasma glucose levels following intravenous administration of glucose [24,25] and
atropine inhibited postprandial PP release but not insulin secretion in Pima Indians [26].
Thus, the importance of cholinergic regulation of insulin and glucagon release in response to a
physiologic mixed meal in humans is unclear.
A recent study suggested that in contrast to mice, human islets are poorly innervated by
parasympathetic (cholinergic) neurons [5]. If so, a neural cholinergic relay to islets would have
little effect on islet physiology. PP is a 36-amino acid peptide produced by a subpopulation of
endocrine cells called PP cells. Circulating PP is undetectable in humans after total pancreatec-
tomy indicating it is produced almost exclusively by the pancreas [27]. Although there are spe-
cies-specific differences [28], in humans PP cells are mainly localized at the periphery of islets
[29–31]. PP is released into the circulation in response to meal ingestion [32] but not to intra-
venous infusion of glucose, amino acids, or fat [27,33]. Atropine blocks PP release in response
to food intake, insulin-induced hypoglycemia, and intravenous infusion of GIP, bombesin, gas-
trin releasing peptide, neurotensin, and bethanechol [34–38]. Truncal vagotomy abolishes PP
release in most cases studied [34,39,40] but a non-vagal mechanism may also contribute to the
regulation of PP release [41]. These collective results suggest that PP secretion is regulated by
vagal and non-vagal cholinergic input to islets.
Xenin-25 is an intestinal peptide reportedly produced by a subset of enteroendocrine cells
[42–45]. Effects of xenin-25 are mediated by activation of neurotensin receptor 1 [46–51]. We
have shown that in sections of human pancreas, neurotensin receptor 1 is detectable on nerves,
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but not islet endocrine cells [33]. Further, during graded glucose infusions, administration of
xenin-25, alone and more so when co-administered with GIP, profoundly increased PP release
in humans [33]. These results strongly suggest that functional cholinergic neurons innervate
human as well as rodent islets. Bethanechol is a charged quaternary amine moiety that does
not cross the blood brain barrier and can thus be used to study the effects of muscarinic cholin-
ergic signaling in the periphery. The purpose of the present study is to determine if bethanechol
and/or xenin-25 increase postprandial cholinergic input to islets and if this signaling is associ-
ated with changes in postprandial glucose, GIP, GLP-1, insulin, C-peptide, glucagon, and PP
levels and insulin secretion rates (ISRs) in humans with normal glucose tolerance (NGT),
impaired glucose tolerance (IGT) and T2DM. Results indicate that increasing postprandial
cholinergic signaling to islets by administration of bethanechol or xenin-25 has little net effect
on insulin or glucagon release.
Materials and Methods
Bethanechol Study
Human Subjects. The study protocol was approved by Washington University’s Human
Research Protection Office and the FDA (IND#103,374) and was registered with ClinicalTrials.
gov (NCT01434901). Studies were performed by the nursing and medical staff in the Clinical
Research Unit of the Institute of Clinical and Translational Sciences of Washington University
after obtaining written informed consent. Subject recruitment was initiated on August 15, 2011
and follow-up for the final participant was completed on July 7, 2014. Subjects were recruited
through Washington University’s Research Participant Registry as well as from the PI’s data-
base of previous participants. After a phone screen, potential participants underwent a screen-
ing visit in the Clinical Research Unit. Subjects were remunerated to encourage completion of
the study. Male and female subjects with NGT (n = 10), IGT (n = 11), and mild T2DM (n = 9)
were studied. Glucose tolerance was defined by the 2-hour plasma glucose level measured dur-
ing a 75-gram oral glucose tolerance test (OGTT) using diagnostic criteria of the American
Diabetes Association [52]. With respect to T2DM, selection criteria were designed to exclude
subjects with advanced beta cell failure: subjects were required to have HbA1c 9%, could not
be using insulin for treatment, had no known history of symptomatic gastroparesis or periph-
eral neuropathy (e.g., burning or tingling in feet) and were enrolled only if oral anti-diabetic
medications could be safely discontinued for 48-hours before each study visit. Women of child-
bearing potential were required to use birth control. Subjects were excluded if they 1) had a his-
tory of chronic pancreatitis and/or risk factors for chronic pancreatitis 2) had a history of
significant gastrointestinal disorders, (e.g. peptide-ulcer disease) 3) were taking non-diabetes
medications known to affect glucose homeostasis and 4) had any significant chronic illness
including heart, renal, liver, inflammatory or malignant disease. The use of choline esters is
contraindicated in persons with hyperthyroidism, coronary artery disease, peptic ulcer, asthma,
chronic bronchitis, or COPD. Subjects with any of these conditions were excluded. Baseline
characteristics for each group were determined during a screening visit following a 12-hour
fast and are shown in Table 1. Based on variance and correlation estimates from the current
study, 10 subjects would provide 80% power when the true differences are 4500 for PP AUC
(sd = 5000, correlation = 0.6) and 29,000 for ISR AUC (sd = 31,623, correlation = 0.6).
Study Design. This is a crossover study in which each participant underwent a series of
meal tolerance tests after a 12-hour overnight fast (Fig 1). Subjects were blinded to treatment.
Each visit was separated by at least 2 weeks. Hemoglobin levels were measured before each
study visit and anyone with a value<11.2 g/dL had that study delayed. In subjects with T2DM
and taking oral diabetes medications, drugs were discontinued for 48 hours before each study
Cholinergic Signaling and Insulin Secretion
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visit. An intravenous catheter was placed into a hand vein. This hand was kept warm in a ther-
mostatically controlled box for sampling arterialized venous blood [53,54]. Subjects with a fast-
ing blood sugar 120 mg/dL were given a bolus of intravenous human insulin (0.01 U/kg) at
30 min intervals as needed to decrease the blood glucose level to 100–120 mg/dL to limit vari-
ability of initial glucose levels. Blood glucose concentrations were stable for longer than 20 min
before administration of bethanechol.
Bethanechol Dosing. Bethanechol is an acetylcholine analog that does not cross the
blood-brain barrier. Oral dosing was based on a survey of the literature as follows. Measuring
the stretch response of the bladder muscle [55,56], the authors reported a progressive increase
in mean cystometric pressure with doses of 50, 100, and 200 mg. Of the 20 subjects in this
study, sweating, diarrhea, chills, bradycardia and hypotension were noted in only 1–2 patients
with the 200 mg dose. The maximal response to oral bethanechol began after ~1 hour and the
action of moderate doses (50–100 mg) persisted for 2–3 hours. Bethanechol has also been used
to treat humans with xerostomia after radiation therapy (25–50 mg 3 times per day [57,58])
and to relieve side effects due to tricyclic antidepressants (25 mg 3 times per day [59]). To
ensure patient safety in our study, bethanechol was administered in escalating doses of 0, 25,
50, and 100 mg during successive meal tolerance tests. Interim results indicated that the 25 mg
dose was ineffective and the 100 mg dose was well-tolerated. Thus, the 25 mg dose was elimi-
nated and the maximal dose was increased to 150 mg. To monitor for symptoms of bethane-
chol toxicity, subjects were placed on continuous cardiac monitoring with blood pressure and
heart rate checked every 15 min. There were no adverse events or unintended effects during
this study.
Meal Tolerance Tests. Boost Plus (Nestle Health Science, Florham Park, New Jersey) is a
liquid mixed meal (360 calories, 14 g of fat, 45 g of carbohydrates, and 14 g of protein). Fasted
subjects ingested Boost Plus and liquid acetaminophen (ACM; 1.5 g/15 mL; Q-PAP Infants’
Table 1. Baseline Demographic and Clinical Characteristics for Bethanechol and Xenin-25 Studies.
Bethanechol Study- NCT01434901 NGT (n = 10) IGT (n = 11) T2DM (n = 9) P Val
2-hour Glucose (mg/dL) 128 ±12 165 ± 19 251 ± 31 <0.0001
Fasting Glucose (mg/dL) 91 ± 5 95 ± 9 115 ± 20 <0.001
HbA1c (%) 5.6 ± 0.2 5.7 ± 0.4 6.2 ± 0.7 <0.02
HbA1c (mmol/mol) 37 ± 2.6 39 ± 4.7 44 ± 7.8 <0.02
BMI (kg/m2) 32 ± 7 31 ± 6 35 ± 6 NS
Age (years) 48 ± 12 45 ± 5 55 ± 9 0.07
Gender (Males/Females) 5/5 8/3 3/6 NS
Fasting PP (pg/mL) 23 ± 15 23 ± 12 20 ± 13 NS
Xenin-25 Study- NCT00949663 NGT (n = 10) IGT (n = 14) T2DM (n = 12) P Val
2-hour Glucose (mg/dL) 118 ±12 162 ± 14 245 ± 23 <0.0001
Fasting Glucose (mg/dL) 95 ± 7 97 ± 7 127 ± 20 <0.0001
HbA1c (%) 5.6 ± 0.3 5.7 ± 0.3 6.2 ± 0.6 <0.001
HbA1c (mmol/mol) 38 ± 2.2 39 ± 1.9 44 ± 4.3 <0.001
BMI (kg/m2) 29 ± 5.1 31 ± 5.3 38 ± 5.7 <0.01
Age (years) 40 ± 11 46 ± 9.1 51 ± 6.4 <0.05
Gender (Males/Females) 4/6 9/5 6/6 NS
Fasting PP (pg/mL) 28 ± 17 24 ± 18 19 ± 10 NS
Group values ± SD are shown for the bethanechol (top) and xenin-25 (bottom) studies. P values were determined by one-way ANOVA for continuous
variables and by Fisher exact test for categorical variables. Note that in the xenin-25 study, PP levels were measured in only 10 subjects per group.
doi:10.1371/journal.pone.0156852.t001
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Drop; Qualitest Pharmaceuticals, Huntsville, AL) over a 3 min period starting at 0 min. The
ACM was included to allow for estimation of the rate of gastric emptying as discussed in our
earlier study [60]. Bethanechol (or placebo) was administered orally with 100 mL of water 1
hour before meal ingestion.
Measurements. Complete metabolic profiles and plasma concentrations of glucose, insu-
lin, C-peptide, glucagon, PP, ACM, total GIP, active GLP-1, and HbA1c were determined as
previously described [33,60,61]. The PP assay involves an extraction step to remove interfering
compounds [33]. A cholinergic symptom survey was administered before, during, and immedi-
ately after each study visit. Any diarrheal episodes during the study were recorded by the nurses
and post-visit episodes determined by telephone follow-up. Heart rate and systolic and dia-
stolic blood pressure and were measured bedside throughout each study visit.
Data Analysis and Statistics. Basal glucose and hormone levels and ISRs were calculated
for each individual by averaging values for the -90, -75, and -60 time points for all study visits.
Means, SDs, and SEMs were then calculated for each group. ISRs were derived by stochastic
Fig 1. Flow diagram for bethanechol study.Diagram is for a non-randomized crossover study with escalating doses of bethanechol in humans with
NGT, IGT, and T2DM.
doi:10.1371/journal.pone.0156852.g001
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deconvolution of the peripheral C-peptide concentrations as in earlier studies [60,61] using
population-based estimates of C-peptide clearance kinetics [62–64]. Differences in baseline
characteristics and/or placebo treatments between groups were evaluated by one-way ANOVA
for continuous variables and fisher exact test for categorical variables. Areas under the curve
(AUCs) were calculated using the trapezoid method and incremental AUCs (iAUCs) were
determined by subtracting baseline AUC from the AUC. Data for AUCs and iAUCs were ana-
lyzed using mixed effects models with subject as a random effect and bethanechol as a fixed
effect using SAS v9.4. Baseline values were used as a covariate for the analysis of the AUCs but
not iAUCs. Paired comparisons were limited to evaluating the effects of 50, 100, and 150 mg
bethanechol compared to placebo. Outcome measures through time were analyzed using the
mixed random effects repeated measures model with covariance structure estimated by a spa-
tial model (SAS 9.4). Subject and subject by drug interaction were random effects.
Xenin-25 Study with Archived Samples
Subjects. The study protocol was approved by Washington University’s Human Research
Protection Office and the FDA (IND#103,374) and was registered with ClinicalTrials.gov
(NCT00949663). Studies were performed in the Clinical Research Unit of the Institute of Clini-
cal and Translational Sciences of Washington University after obtaining written informed con-
sent. Study design (Fig 2), detailed procedures and an initial set of results have been published
[60]. Subject recruitment was initiated on January 1, 2010 and follow-up for the final partici-
pant was completed on March 20, 2012. Subjects had been recruited through Washington Uni-
versity’s Volunteers for Health Office and were remunerated to encourage completion of the
study. No new subjects were enrolled or studied for the present report and only a subset of
archived plasma samples from the prior study were analyzed (Table 1; n = 10 per group).
Patients gave written informed consent for future analyses of archived samples. There were no
adverse events or unintended effects during this study.
Study Design. Briefly, subjects were screened, assigned to groups with NGT, IGT, and
T2DM, and then studied as described above. However, instead of oral bethanechol administra-
tion at minus 60 min, a primed-constant intravenous infusion of xenin-25 (4 or 12 pmoles/kg/
min) or placebo [albumin alone (Alb)] was initiated along with Boost Plus ingestion at time
zero and peptide infusion was continued until the 300-min time point. PP assays and data anal-
ysis are as described above. Group characteristics in the xenin-25 study [60] were very similar
to those in the bethanechol study (Table 1).
Results
Subject Characteristics
For the bethanechol study, values for two-hour glucose, fasting glucose and HbA1c were gener-
ally in the order of NGT<IGT<T2DM (Table 1). Body mass index, age, and gender were not
statistically different between groups. Six of the 9 subjects with T2DM were treated with met-
formin. Of subjects with T2DM, two required insulin before one visit and two required insulin
before three visits. Eight patients were withdrawn from the study because: one had difficulty
swallowing the ACM, two had low baseline blood pressure measurements, two were lost to fol-
low-up, one had anemia, one experienced hypertension during the recovery time and one had
a normal OGTT but was taking metformin. Basal values for each parameter were typically sim-
ilar for each individual at each of their visits but a post hoc analysis of data revealed that subject
#179 (T2DM) had not fasted before the 0 mg visit. Because this subject had received the 25 mg
dose of bethanechol, data for this visit were used in place of the placebo. No studies were
aborted due to bradycardia (<50 beats per min), symptomatic hypotension or lightheadedness,
Cholinergic Signaling and Insulin Secretion
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nausea, vomiting or diarrhea. However, with the 100 mg dose of bethanechol, 2 subjects (1
each with IGT and T2DM) experienced an asymptomatic drop in mean arterial pressure and 1
subject (with IGT) experienced an asymptomatic increase in heart rate. These 3 subjects were
not administered the 150 mg dose of bethanechol.
The postprandial PP response is similar in humans with and without
T2DM
In the bethanechol study, fasting PP levels were not different between groups (Table 1). As
shown in Fig 3A–3C, administration of the placebo (with water) caused small changes in PP
levels over the next 60 min (i.e. prior to meal ingestion). With meal ingestion, levels rapidly
increased in all 3 groups, peaked by 30 min and then slowly returned to baseline values by
~180 min. Group differences in the PP AUCs (Fig 4A–4C) and iAUCs (Fig 5A–5C) from 0 to
300 min in response to placebo did not reach statistical significance (p = 0.30 and p = 0.34,
respectively, by 1-way ANOVA).
Fig 2. Flow diagram for xenin study.Diagram is for a non-randomized crossover study with different doses of xenin-25 in humans with NGT, IGT, and
T2DM.
doi:10.1371/journal.pone.0156852.g002
Cholinergic Signaling and Insulin Secretion
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Bethanechol increases the PP response in humans with IGT, but not
NGT or T2DM
To determine the effects of bethanechol within each group, the meal tolerance tests were repeated
with escalating doses of bethanechol, with each dose administered during a subsequent visit.
Fig 3. Bethanechol differentially affects PP, GLP-1, and GIP responses in humans with NGT, IGT, and T2DM. Subjects with
NGT, IGT, and T2DMwere administered separate meal tolerance tests with placebo (blue dots) or bethanechol at a dose of 50 mg
(green squares), 100 mg (yellow triangles), or 150 mg (inverted red triangles). Plasma levels of PP (Panels A-C), intact GLP-1
(Panels D-F), and total GIP (Panels G-I) were measured at the indicated times before and after meal ingestion. Values represent
group means ± SEMs for subjects with NGT (Panels A, D, G), IGT (Panels B, E, H), and T2DM (Panels C, F, I). The number of
subjects receiving the 0, 50, 100, and 150 mg dose of bethanechol is indicated for each group. Differences in subject number
within each group are because several subjects did not receive the 150 mg dose. GLP-1 and GIP levels were only measured in
samples from individual subjects receiving both the 0 mg and 150 mg doses of bethanechol. P values for the bethanechol effect
(B) and for bethanechol-time interaction (B*T) are indicated in each panel. Statistically significant P values for individual time
points are shown if the bethanechol or bethanechol-time interaction was significant.
doi:10.1371/journal.pone.0156852.g003
Cholinergic Signaling and Insulin Secretion
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Compared to placebo, ingestion of 50, 100, and 150 mg bethanechol had no statistically signifi-
cant effect on PP levels before meal ingestion (Fig 3A–3C; p = 0.76, p = 0.36, and p = 0.35 in
groups with NGT, IGT, and T2DM, respectively). However, after meal ingestion, there were pro-
gressive and bethanechol-dose-dependent increases in the PP levels (Fig 3B; p<0.004), AUCs
(Fig 4B; p = 0.014), and iAUCs (Fig 5B; p = 0.01) in the subjects with IGT, but not NGT or
T2DM (Figs 3A–3C, 4A–4C and 5A–5C). The dose-response in AUCs was linear in the IGT
Fig 4. Bethanechol increases the PP AUC only in humans with IGT. Areas under the curve (AUC) were calculated for
each individual at the indicated dose of bethanechol from data shown in Fig 3. Group means ± SEM are shown. P values
for a bethanechol effect were determined using the mixed effects model and are shown in each panel. Statistically
significant p values for each dose of bethanechol versus placebo are shown only if the bethanechol effect is significant.
doi:10.1371/journal.pone.0156852.g004
Cholinergic Signaling and Insulin Secretion
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group (p = 0.0014). With the 150 mg dose versus the placebo, the AUC and iAUC in the IGT
group increased 1.45-fold (p = 0.0037) and 2-fold (p = 0.0026), respectively.
Bethanechol increases the GLP-1 response in humans with IGT and
T2DM, but not NGT
Next, intact GLP-1 levels were measured in samples from the 0 mg and 150 mg study visits. As
shown in Fig 3D–3F, plasma levels of intact GLP-1 increased rapidly after meal ingestion. With
Fig 5. Bethanechol increases the PP iAUC only in humans with IGT. Incremental AUCs were calculated for each
individual at the indicated dose of bethanechol from data shown in Fig 3. Group means ± SEM are shown. P values were
determined using the mixed effects model. Statistics are as in Fig 4.
doi:10.1371/journal.pone.0156852.g005
Cholinergic Signaling and Insulin Secretion
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placebo, levels peaked at 15–20 min, rapidly declined until 60 min, and then slowly decreased
until the 300 min time point. Bethanechol slightly increased the early GLP-1 responses in the
groups with NGT (Figs 3D and 6D) and IGT (Figs 3E and 6E) but this response was statistically
significant only in the IGT group (p = 0.02 for a bethanechol-time interaction). In contrast,
bethanechol increased the postprandial GLP-1 response in the group with T2DM (Figs 3F and
6F; p = 0.037 for bethanechol effect). The 300-min AUC for GLP-1 was also significantly
increased by the 150 mg dose of bethanechol (p = 0.029; Fig 4F).
Bethanechol increases early GIP release in humans with NGT, but not
IGT or T2DM
As shown in Figs 3G–3I and 6D–4F, plasma levels of total GIP increased rapidly after meal
ingestion, peaked 30 to 60 min later and then continually declined until the 300 min time
point. With the placebo, postprandial peak GIP levels were similar in all 3 groups (Fig 3G–3I).
However, bethanechol administration increased peak GIP levels in the group with NGT, but
not IGT or T2DM. A repeated measures 2-way ANOVA revealed that the interaction between
time and bethanechol was highly significant in the group with NGT (p = 0.02 for a bethane-
chol-time interaction), but not IGT (p = 1.0) or T2DM (p = 0.44). The 300-min GIP AUC (Fig
4G–4I) and iAUC (Fig 5G–5I) were not significantly altered by 150 mg bethanechol in any
group.
Fig 6. Bethanechol differentially affects GIP and GLP-1 responses in humans with NGT, IGT, and T2DM.
Selected data from Fig 3 (-15 to 30 min) are expanded to emphasize differential GLP-1 (panels A-C) and GIP (panels
D-F) responses to the 150 mg dose of bethanechol.
doi:10.1371/journal.pone.0156852.g006
Cholinergic Signaling and Insulin Secretion
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Bethanechol has no effect on glucose homeostasis in humans with
NGT, IGT, and T2DM
Consistent with progressively worsening glucose tolerance, fasting and postprandial plasma
glucose levels (Fig 7A–7C) and ISRs (Fig 7D–7F) as well as their respective AUCs (Fig 8A–8F)
and iAUCS (Fig 9A–9F) with the placebo were in the order of T2DM>IGT>NGT (p<0.0001
and p = 0.04 for respective glucose and ISR AUCs). Moreover, there were rapid and transient
increases in the postprandial glucagon responses in the order of T2DM>IGT>NGT (Fig 7G–
7I) after which glucagon levels decreased (p = 0.05 and p = 0.46 for respective 0–60 and 0–300
minute AUCs). Unlike PP, GLP-1, and GIP responses, there were no statistically significant
bethanechol or bethanechol-time interactions affecting glucose, ISRs, or glucagon levels (Fig
7A–7I), AUCs (Fig 8A–8I), and iAUCs (Fig 9A–9I) within any group. Similarly, bethanechol
did not affect the levels, times to peak value, AUCs and iAUCs for plasma ACM (Figs 7J–7L,
8J–8L and 9J–9L) indicating that it did not affect the rate of gastric emptying.
Symptomatic effects of bethanechol
Subject surveys indicated that there were no dose-dependent effects of bethanechol on diar-
rhea, nausea, vomiting, chest pains, dizziness, heart palpitations, shortness of breath, fever,
chills, blurred vision, or changes in salivation, sweating, or frequency of urination. Meal inges-
tion transiently reduced the group mean arterial blood pressure (7–10 mmHg) and increased
resting heart rate (~8 beats per min) in each group but bethanechol had little additional dose-
dependent effect on either outcome (Fig 10). The absence of significant effects on sweating,
blood pressure, and heart rate are consistent with previous studies by others administering sim-
ilar doses of oral bethanechol [55,56].
Xenin-25 infusion increases the PP response in humans with NGT, IGT,
and T2DM
We previously showed that intravenous administration of an intestinal peptide called xenin-25
during intravenous graded glucose infusions increases the PP response in humans with NGT,
IGT, and T2DM [33]. This PP response is completely inhibited by atropine sulfate (manuscript
in preparation) indicating it is mediated by increased cholinergic input to islets. Thus, we
determined if xenin-25 also amplifies postprandial PP responses and if these responses are
larger than those measured after administration of 150 mg bethanechol. Archived plasma sam-
ples from our previous xenin study were used for these measurements [60]. A detailed exami-
nation of the PP response in humans with NGT showed that basal PP concentrations and
postprandial levels, temporal profiles, and 300-min AUCs were similar to those measured
during placebo administration in the bethanechol study (Not Shown; 300-min PP AUCs =
15,747 ± 2800 vs 17,705 ± 4476, respectively). Hence, timing and route of drug administration
does not affect the PP response. Further, the PP response was increased by xenin-25 infusion
in a dose-dependent fashion (Fig 11A and 11B). Because PP levels peak ~30 min after meal
ingestion, PP levels were measured in additional samples from subjects with IGT and T2DM
prepared 30 min after boost plus ingestion and compared to those from the bethanechol study
(150 mg dose). As shown in Fig 11C–11E, infusion of xenin-25 increased PP levels to a much
greater extent than the highest dose of bethanechol in subjects with NGT, IGT, and T2DM (Fig
3A–3C). However, infusion of xenin had no effect on postprandial ISRs in any group when
normalized to plasma glucose levels [60].
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Fig 7. Bethanechol has no effect on glucose homeostasis in humans with NGT, IGT, and T2DM. Plasma glucose (panels
A-C), glucagon (panels G-I), and ACM (panels J-L) levels and insulin secretion rates (panels D-F) were determined during
meal tolerances as described in Fig 3. Values represent group means ± SEMs for subjects with NGT (Panels A, D, G, J), IGT
(Panels B, E, H, K), and T2DM (Panels C, F, I, L). Symbols are the same as in Fig 4. P values for bethanechol and for
bethanechol-time interaction are indicated in each panel. Data for the 100 mg dose of bethanechol for one subject with T2DM
was excluded from the analysis because baseline values were 4.5 standard deviations from the mean.
doi:10.1371/journal.pone.0156852.g007
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Fig 8. Bethanechol has no effect on glucose homeostasis (AUCs) in humans. Areas under the curves
(AUCs) were calculated from data shown in Fig 7. Group means ± SEM are shown. There were no statistically
significant differences in any response within each group.
doi:10.1371/journal.pone.0156852.g008
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Discussion
Bethanechol does not cross the blood-brain barrier and thus, can be used to study the effects of
muscarinic cholinergic signaling in the periphery on glucose homeostasis. The PP response
was used as a surrogate measure for cholinergic input to islets. Results showed that PP levels,
AUCs, and iAUCs were not different between groups during administration of the placebo.
Bethanechol had relatively little effect on PP levels before meal ingestion but significantly
amplified postprandial PP levels, AUCs (1.45-fold), and iAUCs (2-fold) in humans with IGT
in a dose-dependent fashion. In contrast, bethanechol did not increase the PP response in the
Fig 9. Bethanechol has no effect on glucose homeostasis (iAUCs) in humans. Incremental AUCs were
calculated from data shown in Fig 7. Group means ± SEM are shown. There were no statistically significant
differences in any response within each group.
doi:10.1371/journal.pone.0156852.g009
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groups with NGT and T2DM. Thus, PP cells in humans with IGT, but not NGT or T2DM,
develop hypersensitivity to cholinergic input. Even though the highest dose of bethanechol
increased the PP response in the IGT group, there was no corresponding effect on plasma glu-
cose or glucagon concentrations, ISRs, or gastric emptying. In contrast to bethanechol, infusion
of xenin-25 at 12 pmoles/kg/min increased the PP response nearly 4-fold in all 3 groups. As we
previously reported, this dose of xenin-25 delayed gastric emptying but did not affect ISRs
when normalized to plasma glucose levels [60]. These collective results suggest that increasing
cholinergic input to islets plays only a minor role in regulating postprandial insulin and gluca-
gon secretion in humans.
Consistent with our earlier [33] and present (Figs 3, 4 and 5) studies, others have also
reported that PP levels and responses are not increased in humans with T2DM [65,66]. In con-
trast, some studies concluded that PP levels and responses are increased in T2DM [67,68]. How-
ever, PP levels and responses are known to dramatically increase with age [65,69] and protein
and fat elicit much larger PP responses compared to oral glucose [65]. Additionally, in the pres-
ent study an extraction step was incorporated to remove contaminants that artifactually increase
PP levels in human plasma samples [33]. Further, a dual-antibody sandwich ELISA that does
Fig 10. Bethanechol has little effect on blood pressure or heart rate in humans.Mean arterial blood pressure (MAP) was calculated
from systolic (SP) and diastolic (DP) blood pressure readings using the formula MAP = DP+1/3(SP-DP). Values represent group
means ± SEMs for subjects with NGT (Panels A, D), IGT (Panels B, E), and T2DM (Panels C, F). Symbols and statistics for bethanechol-
time interaction are as described in Fig 3.
doi:10.1371/journal.pone.0156852.g010
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not cross react with highly related NPY and PYY or with other gut peptides was used for our PP
measurements. This type of ELISA exhibits greater antigen specificity than that obtained using a
single antibody RIA. Hence, the reason(s) for the discrepancies in PP responses in humans with
versus without T2DM is likely due to differences in assay procedures and specificities but also
raises the intriguing possibility that propancreatic polypeptide may be differentially processed
to peptides with unique bioactivities in humans with NGT, IGT, and T2DM.
An unexpected finding was that bethanechol had complex and differential effects on GLP-1
and GIP release in humans with NGT, IGT, and T2DM during mixed meal tolerance tests.
Specifically, bethanechol increased the GLP-1 response in the groups with IGT and T2DM
Fig 11. Xenin-25 profoundly increases PP release in humans with NG, IGT, and T2DM. (A) PP levels were measured
at the indicated times in subjects with NGT during meal tolerance tests with albumin alone (Alb; blue dots) or xenin-25 at a
dose of 4 pmol/kg/min (Lo-Xen; yellow squares) or 12 pmol/kg/min (Hi-Xen; red triangles). As in the bethanechol study, the
liquid meal was ingested from 0–3 min. (B) 0–300 min AUCs for data in panel A are shown. (C-E) PP levels were measured
in the samples collected before (0 min) and 30 min after meal ingestion in humans with NGT (Panel C), IGT (Panel D), and
T2DM (Panel E) during a primed-continuous infusion of xenin-25 (12 pmoles/kg/min).
doi:10.1371/journal.pone.0156852.g011
Cholinergic Signaling and Insulin Secretion
PLOS ONE | DOI:10.1371/journal.pone.0156852 June 15, 2016 17 / 22
(T2DM> IGT) but increased GIP release only in the group with NGT. Our study was not
designed to determine if these were direct or indirect effects of bethanechol action on intestinal
K and/or L cells. In spite of this, changes in the patterns for GIP and GLP-1 release were not
accompanied by alterations in profiles for ISRs, rate of gastric emptying, plasma glucagon lev-
els, and glucose concentrations within any group. This is consistent with previous results from
our laboratory showing that postprandial, endogenously released, circulating GLP-1 plays little
role in regulating postprandial insulin secretion in humans [60]. That bethanechol altered
GLP-1 release but not insulin secretion in the group with T2DM is also consistent with the
well-known observation that the response to endogenous incretins is blunted in T2DM [70].
Thus, strategies to increase release of endogenous GLP-1 in humans with T2DMmay not rep-
resent an effective intervention for treating this disease. It is also important to note that the
GLP-1 response is as rapid as that for GIP even though most GLP-1 producing cells are located
in the distal intestine whereas GIP-producing cells reside predominantly in the proximal gut.
This suggests that early GLP-1 release is mainly under neural rather than nutritional control.
Consistent with this idea, a host of neurotransmitters and peptides increase GLP-1 release in
the vascularly perfused rat ileum [71].
Several limitations to the current study should be addressed. First, bethanechol had only
modest effects on the PP, GIP, and GLP-1 responses within each effected group. Although the
doses used in our study are known to affect the stretch response of the bladder muscle without
eliciting hypotension or bradycardia [55,56], it is possible that higher doses would have exerted
greater effects and thus, possibly altered glucose levels, ISRs, glucagon concentrations, gastric
emptying, or other factors that regulate glucose homeostasis. However, the bethanechol doses
used in the current study revealed that physiologically relevant changes in endogenous PP,
GIP, and GLP-1 release do not affect postprandial glucose homeostasis. This result could have
potentially been masked by a greater degree of cholinergic agonism. However, that xenin-25
profoundly increased PP release but not ISRs argues against this. A second limitation is that
bethanechol activates all muscarinic receptors in the periphery and thus, the current study
assessed the effects of stimulating multiple superimposed cholinergic signaling pathways and it
is possible that numerous positive and negative responses exactly offset each other. If this is the
case, it would suggest that cholinergic signaling could possibly act to maintain a pre-established
“set-point” for glucose homeostasis without increasing insulin secretion. It should be noted
that of the 5 known muscarinic acetylcholine receptors, it is the M3 subtype that increases insu-
lin release from beta cells [7–12]. Thus, even though a xenin-25-mediated increase in choliner-
gic input to islets did not amplify ISRs, M3 subtype-specific agonists may still represent a
therapeutic strategy for increasing ISRs in T2DM. Third, the lower doses of bethanechol may
not have remained active for the duration of the study though it is clear that the 150 mg dose
had effects in all groups and the PP response in the group with IGT was bethanechol dose-
dependent. Finally, our results compared the effects of cholinergic signaling on postprandial
ISRs and glucagon levels in humans with NGT, IGT, and T2DM. However, our results may not
be applicable to other metabolic or pathophysiologic conditions.
Conclusions
In spite of the limitations, our results indicate that bethanechol has different effects on PP,
GIP, and GLP-1 release in humans with NGT versus IGT versus T2DM. Even with these differ-
ences, bethanechol had no measureable effect on glucose homeostasis in any group. As shown
in this as well as our earlier study [33], infusion of xenin-25 in humans with NGT increased
the postprandial PP response nearly 4-fold and reduced the GLP-1 response 6-fold but had no
effect on insulin or glucagon responses. These results suggest that cholinergic signaling and
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circulating GLP-1 play only minor roles in regulating glucose homeostasis in humans. Because
islet responses to endogenously released circulating incretins [70] but not to exogenously
infused GIP [61] or GLP-1 [72,73] are blunted in T2DM, it is critical to determine if and how
GLP-1 and GIP released from respective intestinal L and K cells regulate glucose homeostasis
in humans. Moreover, our data suggest that cholinergic mechanisms that regulate insulin
secretion are different in humans and mice and thus, extreme caution must be exercised when
extrapolating results from animals to humans.
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